Among therapeutic proposals with current tests in cancer patients, we have PAK_5339, which is a drug that inhibits PAK1 and PAK2, proteins related to the activation of cell survival by different mechanisms, such as the metabolism of Bcl-2 in the mitochondria, the modulation of the cell motility, and the activation of the PI3K-AKT/mTOR pathway (Yao et al., 2020; Liu et al., 2021). Here, AKT1 is linked to cancer.